Ensysce Biosciences, Inc. ENSC 深 滬
已收盤 02-06 16:00:00 美东时间
0.4614
+0.002
+0.52%
華盛通- 最 高0.488
- 今 開0.48
- 成交量 26.41万股
- 最 低 0.378
- 昨 收 0.459
- 總市值 167.59万
- 52周最高 6.14
- 市盈率 靜 --
- 換手率 7.27%
- 52周最低 0.378
- 委 比 -90.48%
- 總股本 363.23万
- 歷史最高 61632.00
- 量 比 1.39
- 振 幅 23.97%
- 歷史最低 0.378
- 每 手 1
- 風險率 1.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ensysce Biosciences Receives Notice Of Allowance From Brazilian Patent Office For Issuance Of Patent For Additional Opioid Families For Company's Trypsin Activated Abuse Protection, Multi-Pill Abuse Resistance Technologies
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose,
01-21 21:09
Ensysce Biosciences Receives European Patent Allowance For PF8026, Novel ADHD Prodrug With TAAP And MPAR Abuse‑Deterrent Technologies
~ New ADHD pipeline leverages TAAP™ and MPAR® technologies to improve safety for patients ~SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 8, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the
01-08 21:06
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Athira Pharma (NASDAQ:ATHA) stock increased by 30.6% to $5.4 during Th...
2025-12-18 20:05
Ensysce Biosciences Receives U.S. Patent And Trademark Office Notice Of Allowance For New Patent Covering Multi-Pill Abuse Resistance Technology
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize abuse and
2025-12-02 21:08
Ensysce Biosciences Secures $4M Financing To Accelerate Phase 3 Development Of PF614 And Advance Abuse- And Overdose-Resistant Pain Therapies
~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~SAN DIEGO, CA / ACCESS Newswire / November 17, 2025 / Ensysce Biosciences, Inc.
2025-11-17 21:16
Ensysce Biosciences Q3 EPS $(1.29) Misses $(0.84) Estimate, Sales $493.104K Miss $700.000K Estimate
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(0.84) by 52.66 percent. This is a 229 percent decrease over earnings of $1.00 per share
2025-11-15 05:18
Ensysce Biosciences Showcases TAAP and MPAR Platforms In PAINWeek2025 Symposium Highlights, Redefining Opioid Safety Amid Global Crisis
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain therapeutics designed to minimize abuse and overdose risk, has released video
2025-10-10 20:17
Ensysce Biosciences Advances Opioid Therapy Innovations
Ensysce Biosciences, Inc. ( ($ENSC) ) has released its Q2 earnings. Here is a b...
2025-08-14 12:27
Ensysce Biosciences Q2 EPS $(0.79) Beats $(1.18) Estimate, Sales $1.371M Beat $650.000K Estimate
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(1.18) by 33.05 percent. This is a 76.06 percent increase over losses of $(3.30) per share
2025-08-14 04:20
Ensysce Biosciences shares are trading higher after the company announced it received FDA feedback for PF614-MPAR.
Ensysce Biosciences shares are trading higher after the company announced it re...
2025-07-31 21:06
